Shares of InterMune (ITMN +8.8%) run higher after the company announces that its lung disease...
Shares of InterMune (ITMN +8.8%) run higher after the company announces that its lung disease drug Esbriet gained approval with a Germany review committee. The action clears a path for the treatment to be approved by the nation's health insurers and helps increase confidence that France will also allow the therapy.
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs